Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

75.33 +4.13 (+5.80%)
Streaming Delayed Price Updated: 1:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,598,202
Open 74.99
Bid (Size) 75.32 (5)
Ask (Size) 75.33 (1)
Prev. Close 71.20
Today's Range 74.50 - 75.81
52wk Range 60.47 - 76.56
Shares Outstanding N/A
Dividend Yield 1.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
AZN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Performance

YTD
+10.13%
+10.13%
1 Month
+14.38%
+14.38%
3 Month
+13.11%
+13.11%
6 Month
+17.32%
+17.32%
1 Year
-0.46%
-0.46%

More News

Read More
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Via Chartmill
Looking At AstraZeneca's Recent Unusual Options Activity
Via Benzinga
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
Via Investor's Business Daily
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Q1 2024 results
From AstraZeneca
Via Business Wire
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
European Stock: AstraZeneca
Via Talk Markets
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Via Benzinga
Topics Brexit
Exposures Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
From AstraZeneca
Via Business Wire
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Via Benzinga
Exposures Product Safety
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
Via Benzinga
Exposures Product Safety
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.